Hélène M. Faessel

Pevonedistat (<scp>MLN</scp>4924), a First‐in‐Class <scp>NEDD</scp>8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

Ronan Swords, Harry P. Erba, Daniel J. DeAngelo et al. · British Journal of Haematology · 2015 · 234 citations · Full text

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Ronan Swords, Steven Coutré, Michael B. Maris et al. · Blood · 2018 · 198 citations · Full text

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor et al. · Clinical Cancer Research · 2015 · 188 citations · Full text

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen et al. · Clinical Cancer Research · 2015 · 163 citations

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

Shailender Bhatia, Anna C. Pavlick, Peter D. Boasberg et al. · Investigational New Drugs · 2016 · 112 citations · Full text